This randomised, double blind, placebo-controlled study sought to determine the survival ofLactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG when ingested as part of a low-fat probiotic spread in 42 healthy human volunteers.

Volunteers were randomly assigned to one of three treatment groups provided with placebo spread (n=13), spread with a target dose of 1 x 10^9 CFU of Lactobacillus reuteri DSM 17938 (n=13), or spread with a target dose of 5 x 10^9 CFU of Lactobacillus rhamnosus GG (n=16) daily for 3 weeks. A significant increase in bacterial counts for both strains was recorded in faecal samples after 3 weeks of daily consumption of the low-fat probiotic spread.

Conclusion: Low-fat spread is a suitable carrier for these probiotic strains.



Dommels YEM, Kemperman RA, Zebregs YEMP, Draaisma RB, Jol A, Wolvers DAW, Vaughan EE, Albers A. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnous GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. Appl Environ Microbiol. 2009;75:6198–6204.

Crawling baby

For the avoidance of doubt, BioGaia’s products are food supplements, and the information on this part of the website should not be interpreted as our products are intended to diagnose, treat, cure or prevent any disease.

The information on this part of the website is intended only for health care and business professionals. If you are not a health care or business professional and would like to learn more about the indications BioGaia works with, please visit our Expertise pages.

Please read terms & conditions before accepting. By clicking on the button “I acknowledge and accept” you confirm that you are a healthcare or business professional and have read and understood this disclaimer including the terms and conditions.